Plant ID: NPO18951
Plant Latin Name: Ligusticum sinense
Taxonomy Genus: Ligusticum
Taxonomy Family: Apiaceae
NCBI TaxonomyDB:
49555
Plant-of-the-World-Online:
n.a.
Analgesic; Antifungal; Antirheumatic; Antispasmodic; Diaphoretic; Emmenagogue; Sedative
South Korea; China
TSHR; NPSR1; | |
FFAR1; FFAR4; | |
ACHE; | |
MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; CSNK2A1; | |
CA2; CA12; CA9; CA14; CA7; | |
ESR2; | |
ALOX12; HSD17B1; HSD17B10; ALOX15; NOX4; POLB; | |
KDM4E; | |
MMP9; MMP1; MMP2; | |
NFKB1; | |
FUT7; | |
LMNA; FABP3; FABP4; THPO; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.893E-11 | 7.181E-07 | CA12, CA14, CA2, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.420E-08 | 3.385E-05 | CA12, CA14, CA2, CA7, CA9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.842E-08 | 3.637E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.162E-08 | 3.776E-05 | ALOX12, ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.018E-07 | 7.153E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2A6 |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 1.295E-07 | 8.546E-05 | ALOX12, AURKB, AXL, CDK1, CSNK2A1, FFAR4, IGF1R, KDR, LMNA, MMP9, NFKB1, PIM1 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.502E-07 | 9.620E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.798E-07 | 1.451E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, NOX4 |
BP | GO:0009987; cellular process | GO:0071310; cellular response to organic substance | 7.965E-07 | 3.540E-04 | ALOX15, AXL, CYP1A1, CYP1B1, FABP4, FFAR4, FLT3, IGF1R, KDR, MMP2, NFKB1, NOX4, TSHR |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.795E-07 | 4.182E-04 | CA12, CA2, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.054E-06 | 4.414E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 1.602E-06 | 6.459E-04 | ALOX12, CDK1, CSNK2A1, FLT3, IGF1R, KDR, MMP2, MMP9, PIM1, THPO, TSHR |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.806E-06 | 7.023E-04 | ALOX12, ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, HSD17B1, HSD17B10, KDM4E, NOX4 |
BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 1.960E-06 | 7.489E-04 | AXL, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, FABP3, FFAR1, FLT3, NFKB1 |
BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.086E-06 | 7.830E-04 | CA2, CA9, CDK1, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FLT3, NFKB1, NOX4 |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 3.383E-06 | 1.169E-03 | AURKB, CSNK2A1, FLT3, IGF1R, KDR, PIM1 |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 4.396E-06 | 1.387E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 4.396E-06 | 1.387E-03 | ALOX12, ALOX15 |
BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 7.903E-06 | 2.390E-03 | CA2, CA9, CSNK2A1, CYP1A2, FABP3, FFAR4, FLT3, NFKB1, TSHR |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.317E-05 | 3.497E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.317E-05 | 3.497E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.317E-05 | 3.497E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.526E-05 | 3.956E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 2.007E-05 | 4.698E-03 | AXL, CDK1, CSNK2A1, FLT3 |
BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 2.139E-05 | 4.902E-03 | ALOX12, CA12, CA2, CA7, FABP3, FABP4, FFAR1, MET, NOX4, NPSR1 |
BP | GO:0050896; response to stimulus | GO:0010243; response to organonitrogen compound | 2.484E-05 | 5.512E-03 | CDK1, FABP3, FFAR4, FLT3, IGF1R, MMP2, NFKB1, NOX4, TSHR |
MF | GO:0005488; binding | GO:0005504; fatty acid binding | 2.506E-05 | 5.512E-03 | FABP3, FABP4, FFAR4 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.630E-05 | 5.514E-03 | CYP1A1, CYP1A2 |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 4.378E-05 | 8.290E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 4.438E-05 | 8.331E-03 | AXL, FLT3, IGF1R, KDR, MET |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 5.074E-05 | 9.207E-03 | CYP19A1, CYP1A1, CYP2A6 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.709E-10 | 2.085E-08 | CA12, CA2, CA7, CA9, CA14 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 5.568E-08 | 3.396E-06 | HSD17B1, CYP1A1, CYP1B1, CYP19A1, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.190E-07 | 4.838E-06 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.447E-05 | 3.644E-04 | FLT3, MMP1, MMP2, MET, MMP9, NFKB1, IGF1R |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.493E-05 | 3.644E-04 | CYP2A6, CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 5.710E-05 | 7.740E-04 | MMP2, KDR, MMP9, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 3.219E-05 | 5.610E-04 | FLT3, MMP9, MET, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.368E-05 | 4.815E-04 | CYP2A6, CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 7.495E-05 | 8.956E-04 | CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.167E-04 | 2.203E-03 | FLT3, PIM1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 8.075E-05 | 8.956E-04 | MMP1, MMP2, MMP9 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 3.377E-04 | 2.943E-03 | PIM1, CYP1B1, MMP9, MET, NFKB1 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 7.532E-04 | 5.405E-03 | CYP2A6, FUT7, HSD17B1, CYP1A2, ALOX15, CYP1A1, ALOX12, CYP19A1, HSD17B10 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.198E-04 | 2.943E-03 | CYP2A6, CYP1A2, CYP1A1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 4.685E-04 | 3.572E-03 | CSNK2A1, MET, IGF1R |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.159E-03 | 7.182E-03 | MMP2, PIM1, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.177E-03 | 7.182E-03 | KDR, MET, NFKB1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 3.814E-04 | 3.102E-03 | FABP3, FABP4, MMP1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.094E-03 | 7.182E-03 | MMP2, MMP9, ESR2 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.607E-03 | 9.338E-03 | CYP1A2, ALOX15 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 4.084E-05 | 6.228E-04 | CYP2A6, CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; MMP9; MMP2; CA9; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; CYP19A1; CA9; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; FFAR1; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
NA: NA | Edema | NA | CA2; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; NFKB1; FLT3; ACHE; MMP9; MMP2; CA9; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
NA: NA | GIST | NA | FLT3; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; MMP2; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |